Byotrol strikes deal with the NHS

BYOTROL’S superbug cleaning technology has been signed up by the NHS after years of trials.

It will be immediately available for use in NHS hospitals though the NHS Supply Chain.

The deal is a major boost for the Manchester business which yesterday said it planned to launch a £4m share issue to bolster its finances.

Deputy chairman Stephen Falder, said: “This represents a significant step for the company and the news comes on the back of a five-year programme to drive adoption of our technology into the NHS.”

AIM-listed Byotrol, whose anti-microbial technology targets superbugs such as MRSA, admitted yesterday that cash reserves had been depleted by fewer sales than expected this year.

Unaudited management accounts to September 30 show turnover of £400,000 and a loss, before share scheme charges, of £1.1m.

It said cash from the share offer would be used for working capital and to equip a new technical centre. Shareholders will consider the plan on November 19.

Interim results for the six months to September 30 are due on November 24.